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(MRI) in order to evaluate further the contribution of MRI in the definition of pituitary GH reserve in GH-deficient patients. Twenty-nine patients (mean age 14.5 \m=+-\4.0 years ) were studied. Group I comprised 13 patients: seven with isolated GH deficiency (IGHD) (group Ia) and six with multiple pituitary hormone deficiency (MPHD) ( IGHD and normal morphology of the pituitary gland. Growth hormone and IGF-I levels were measured during saline infusion at 08.30\p=n-\ 09.00 h, as well as after infusion of GHRH (1\p=n-\29) at escalating doses for 3 h: 0.2\g=m\g/kg at 09.00\p=n-\ 10.00h. 0.4\g=m\g/kg at 10.00\p=n-\11.00h. 0.6\g=m\g/kg at 11.00\p=n-\12.00h and an intravenous bolus of 2 \ g=m\ g/ kg at 12.00h. In the group I patients, the peak GH response to GHRH(1\p=n-\29) was delayed (135\ x=req-\ 180 min) and extremely low (median 2mU/l). In group II it was delayed (135\p=n-\180 min), high (median 34 .8mU/l) and persistent (median 37.4mU/l at 185\p=n-\210min). In group III the peak response was high (median 30.8 mU/l) and relatively early (75\p=n-\120 min) but it declined rapidly (median 14.4 mU/l at 185-210min). In one group I patient, GH response increased to 34 .6mU/l. The mean basal value of IGF-I levels was significantly lower in group I(0.23 \ m=+-\ 0.05 U/ml) than in groups II(0.39 \ m=+-\ 0.13U/ ml, p < 0.01) and III (1.54 \ m=+-\0.46 U/ml, p < 0.001) and did not vary significantly during the GHRH(1\p=n-\29) infusion. The present study demonstrates that the impaired GH response to 3h of continuous infusion of escalating doses of GHRH(1\p=n-\29) was (6) (7) (8) (9) . In all these studies the diagnosis of GH respectively, at the levels of 0.7 U/ml and 0.33 U/ml, and 5.2% and 9.4% at the levels of 1.5 U/ml and 1.3U/ml. Cross-reactivity was less than 0.01% for GH, porcine glucagon, TSH 
IGF-1 levels
The mean basal (time 0) IGF-I levels were 0.22 ± 0.06 (median 0.08 U/ml) in group la and 0.24±0.09 U/ml (median 0.11 U/ml) in group lb. In group I as a whole they were 0.23 ±0.05 U/ml (median 0.11 U/ml), which is significantly lower than in groups II (0.39 ±0.13 U/ml, < 0.01. median 0.29 U/ml) and III (1.54 ± 0.46 U/ml, < 0.001; median 1.35 U/ml) (Figures 4 and 5) . The mean IGF-I levels did not vary significantly during the GHRH(l-29) infusion.
Discussion
The GH response to a 3 h infusion of escalating doses of GHRH(l-29) in patients with GH (24) . The concomitant GH treatment seems to counteract some of these effects, improving the ability of the gland to respond to an acute GHRH challenge by increasing the cellular activity (25) .
In the patients with normal pituitary morphology, the pattern of GH response to GHRH (1-29) was similar to that described previously in normal subjects (1-5). One wonders whether these patients are hypothalamic GHRH-dependent GH-deficient; if so, it remains ques¬ tionable why the pituitary gland is still of the normal size and quickly responsive (26) . Evidence of normal spontaneous GH secretion, probably stress-related, in two patients suggests that they were transient or falsepositive GH-deficient (27 (31, 32) and in animals (33 
